Showing results (1081-1090 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|January 1, 1996
Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 daysI Rassmann, H Schrödel, T Schilling, et al.
Investigational New Drugs|January 1, 1996
Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced colorectal carcinomaN Belman, E M Bonnem, H A Harvey, et al.
Investigational New Drugs|January 1, 1996
Phase II study of mitonafide in non-small cell lung cancer (NSCLC)A Casado, R Rosell, R García-Gómez, et al.
Investigational New Drugs|April 21, 2015
A phase 1 study of ABT-806 in subjects with advanced solid tumorsJames M Cleary, David A Reardon, Nilofer Azad, et al.
Investigational New Drugs|April 21, 2015
Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitroPushpendra Singh, Felix Bast
Investigational New Drugs|May 5, 2015
Pharmacokinetic assessment of dacomitinib (pan-HER tyrosine kinase inhibitor) in patients with locally advanced head and neck squamous cell carcinoma (LA SCCHN) following administration through a gastrostomy feeding tube (GT)Joanne W Chiu, Kelvin Chan, Eric X Chen, et al.
Investigational New Drugs|May 8, 2015
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancerZahi Mitri, Cansu Karakas, Caimiao Wei, et al.
Investigational New Drugs|May 8, 2015
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumorsMark J Ratain, David Geary, Samir D Undevia, et al.
Investigational New Drugs|May 1, 2015
Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancerHidehito Horinouchi, Noboru Yamamoto, Yutaka Fujiwara, et al.
Investigational New Drugs|May 3, 2015
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignanciesGuillermo Garcia-Manero, Raoul Tibes, Tapan Kadia, et al.
Pageof 372